Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 2/20 | 0.46 |
| ▸ | MMP9 | P14780 | 2/20 | 0.46 |
| ▸ | MMP14 | P50281 | 1/20 | 0.45 |
| ▸ | LIPE | Q05469 | 2/20 | 0.45 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2219745 | 0.79 | ACHE (0.54) | MEN1KMT2AAKR1C3EPHX2HTR2A | |
| SCHEMBL29460579 | 0.78 | MEN1 (0.62) | MEN1KMT2AEPHX2L3MBTL1 | |
| SCHEMBL19215178 | 0.77 | MEN1 (0.62) | MEN1KMT2AEPHX2HTR2ALIPE | |
| SCHEMBL13201298 | 0.77 | EPHX2 (0.47) | MEN1KMT2AAKR1C3EPHX2HTR2A | |
| SCHEMBL25317014 | 0.77 | ALDH1A1 (0.43) | KMT2APSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2171815 | 0.77 | EPHX2 (0.61) | MEN1KMT2AEPHX2HTR2ALIPE | |
| SCHEMBL18177501 | 0.76 | ALDH1A1 (0.70) | MEN1KMT2AEPHX2LIPEL3MBTL1 | |
| SCHEMBL2220869 | 0.76 | TRPA1 (0.53) | AKR1C3MMP2PSEN1PSEN2APH1B | |
| SCHEMBL20456429 | 0.76 | USP2 (0.65) | MEN1KMT2AEPHX2L3MBTL1 | |
| SCHEMBL7955680 | 0.76 | MEN1 (0.60) | MEN1KMT2AEPHX2LIPEEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178119-A1 | Bridged N-Bicyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | US | claimed |
| EP-1915371-A2 | BRIDGED N-BICYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | Elan Pharmaceuticals Inc. (US) | 2008-04-30 | — | — | EP | claimed |
| WO-2007024651-A2 | BRIDGED N-BICYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2007-03-01 | — | — | WO | claimed |
| US-20110178119-A1 | Bridged N-Bicyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| EP-1915371-A2 | BRIDGED N-BICYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | Elan Pharmaceuticals Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007024651-A2 | BRIDGED N-BICYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178119-A1 | Bridged N-Bicyclic Sulfonamido Inhibitors of Gamma Secretase | BACE1, BACE2, PSEN1 | MEN1 2563/4885KMT2A 2774/4885AKR1C3 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.